Tyrosine News and Research

RSS

The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals

Researchers determined the prevalence of antibodies against the SARS-CoV-2 spike glycoprotein following three or more doses of COVID-19 vaccines among immunocompromised individuals.

17 Feb 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

Study reviews mechanistic data on new methods of allergy prevention and treatment

In a recent article published in Science Translational Medicine, researchers reviewed the cause and the underlying pathophysiology of allergic diseases.

23 Jan 2023

S. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein A

Researchers assessed the impact of Staphylococcus aureus (S. aureus) on SARS-CoV-2 replication.

17 Jan 2023

SARS-CoV-2 WA1/2020, Delta and Omicron strains found to infect human sensory neurons

Researchers evaluated the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the peripheral nervous system (PNS).

13 Jan 2023

Newly identified gene drives development of the second most common type of lung carcinoma

A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might someday be treated.

9 Jan 2023

Scientists explore efficacy of small molecule drugs against severe COVID-19 in vitro

Researchers evaluated the efficacy of small molecule drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro.

29 Dec 2022

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS).

28 Dec 2022

Enzyme inhibition reduces cancer-related bone loss and the number of bone metastases

In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.

20 Dec 2022

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Study shows how dietary saturated/trans fats promote liver tumorigenesis

Fatty foods harm our health. Prior research has established a link between the consumption of dietary fats and non-alcoholic fatty liver disease, which subsequently leads to inflammation and tumor formation in the liver.

7 Dec 2022

Study implicates gut microbiome health in Parkinson's disease

A new study published in the journal Nature Communications discusses the links between this condition that affects the brain and changes in the gut microbiome that may predate brain changes.

1 Dec 2022

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Researchers used ribonucleic acid (RNA) sequence data to understand the association between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML).

29 Nov 2022

New chemical probe can selectively inhibit human COQ8A protein in cells

Inhibition of the COQ8 protein could be beneficial in the treatment of diseases such as cancer. COQ8 is needed for the biosynthesis of coenzyme Q, also known as ubiquinone.

28 Nov 2022

Flavonoids with potential to fight allergies and inflammation

In a recent study published in the Biomedicine & Pharmacotherapy journal, researchers explored the anti-allergic and anti-inflammatory properties of flavonoids.

28 Nov 2022

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

BGI has currently published over 440 SCI (Science Citation Index) papers in the field of cancer research, with a cumulative impact factor of over 4,000 points.

From BGI Genomics 23 Nov 2022

Cancer Research Horizons, Newcastle University extend strategic drug discovery alliance with Astex Pharmaceuticals

Cancer Research UK’s newly launched innovation engine, Cancer Research Horizons, and Newcastle University, have announced a further significant extension of their strategic drug discovery alliance with Astex Pharmaceuticals (UK) (‘Astex’), a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics.

22 Nov 2022

Researchers identify a conserved site on SARS-CoV-2 spike that a broadly neutralizing macrocyclic peptide can target

Researchers explored the efficiency of a macrocyclic peptide in inhibiting the SARS-CoV-2 spike protein.

17 Nov 2022

Oral deucravacitinib shows promise in patients with active lupus

Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus.

14 Nov 2022